Robert Plenge MD, Ph.D., Appointed Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge MD., Ph.D., to the company’s Board of Directors, effective September 10, 2026. Robert Plenge MD on Advancements in Genetic Research Dr. Plenge is Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, where he leads the organization’s […]